Prior studies of Trisomy 21 (Down’s syndrome) showed that any variation in the dose of the protein kinase DYRK1A modifies the GABAergic and glutamergic systems involved in the expression of this syndrome, but the mechanisms involved have yet to be explained.

The DYRK-DOWN project aims to understand the role and functions of this kinase DYRK1A, as a key step towards developing a candidate drug which will inhibit it, with a view to treating Down’s syndrome. DYRK1A inhibitors in the Leucettine class (alkaloids from a marine sponge) have already been chemically synthesised by the company ManRos Therapeutics; these will then be tested.

The DYRK-DOWN project aims to prepare the groundwork for treating people with Down’s syndrome at both an early and advanced stage, by identifying the molecules to target and providing the pharmacological tools to do so. These will be of marine origin, and may potentially prevent or treat the developmental aspect of Down’s syndrome.

  • - ManRos Therapeutics / R&D, Roscoff
Research centers
  • - Centre Européen de Recherche en Biologie et en Médecine (CERBM), Institut de Génétique de Biologie Moléculaire et Cellulaire (IGBMC), Illkirch  [Project Developer]
  • - Centre Européen de Recherche en Biologie et en Médecine (CERBM), Institut de génétique et de biologie moléculaire et cellulaire (UM 41 - UMR 7104 - UMR_S 1258) IGBMC Illkirch
  • - Institut National de la Santé et de la Recherche Médicale (INSERM) Bordeaux
  • - Université Denis Diderot - Paris 7 Unité de biologie fonctionnelle et adaptative (BFA), Paris
- Agence Nationale de la Recherche
Overall budget
1 922 K€